QT 5, Inc. Establishes Medical & Regulatory Advisory Board


WESTLAKE VILLAGE, Calif.--March 10, 2003--QT 5, Inc. (OTCBB:QTFV) announced
today that it has assembled a distinguished group of medical and legal
professionals to provide guidance and leadership for the development and
introduction of a wide array of new products. CEO, Timothy Owens said, "We are a
company that is focused on the pioneering of leading edge lifestyle and
healthcare products. Because much of what we are doing has never been done
before, we have created this board and staffed it with individuals who are
recognized and respected as leaders in their disciplines. Each one of these
people has expressed tremendous enthusiasm for the potential of our products as
well as a keen awareness of the challenges and opportunities that face us. As is
evidenced in the following credentials, we are very fortunate to have them on
our team."


DR. LEONARD MAKOWKA, MD. PHD. leads the QT 5 advisory board as Senior Medical
Research Advisor. He is a distinguished clinical surgeon, transplantation
surgeon and medical researcher and is recognized as one of the World's leading
authorities in hepatic science (study relating to the liver). Dr. Makowka has
retired from active practice of medicine and is pursuing investment strategies
in healthcare and other technology areas. He has successfully served in numerous
executive positions. From 1995 to 1997, Dr. Makowka was the Executive Director
of the Comprehensive Liver Disease and Treatment Center and Director of the
Liver Transplant Program at St. Vincent's Medical Center in Los Angeles, CA.
Between 1989 and 1995, Dr. Makowka was the Chairman of the Department of Surgery
and the Director of Transplantation Services at Cedars-Sinai Medical Center in
Los Angeles, CA. He was also Professor of Surgery at the UCLA School of
Medicine. Beginning in 1985, in Canada, until relocating to Los Angeles in 1989,
Dr. Makowka trained under Dr. Thomas Starzl, the pioneer of liver
transplantation, and was appointed Associated Professor in the Department of
Surgery at the University of Pittsburgh. In 1982, Dr. Makowka began his
residency at the University of Toronto, where in his final year he was appointed
Chief Resident of Surgery. Dr. Makowka has performed hundreds of hepatobiliary
and liver transplant procedures. Dr. Makowka received his M.D. degree from the
University of Toronto Medical School in 1977, and Master of Science and
Doctorate of Philosophy from the University of Toronto's Department of Pathology
in 1979 and 1982. Dr. Makowka has published over 400 articles and chapters in
both clinical and basic scientific research and continues to lecture worldwide.


DR. HOWARD WILNER, MD has joined the QT 5 Advisory Board as Senior Research
Associate. He received his B.A. from Brooklyn College, and his M.D. from New
York University School of Medicine. After Post Graduate Training in Internal
Medicine, Nephrology, and Clinical Pharmacology and completion of Military
Service, Dr. Wilner entered the private practice of medicine. He is Board
Certified by the American Board of Internal Medicine as well as the Subspecialty
Board of Nephrology. Dr. Wilner has had a distinguished career in medicine as
both a Medical Executive and Practicing Physician. After serving as the Clinical
Chief of Medicine at Cedars-Sinai Medical Center, he was the Executive Director
of the Cedars-Sinai Comprehensive Cancer Center from 1988 through 1997. He
remains on the Active Staff of the Hospital and in Private Practice.


DR. LEANDRA EVEN, N.D., A.P.H. will serve as Medical Research Advisor for the
Company's Homeopathic products. She has a B.A. from Washington State University
and a B.S. from Bastyr University. Her doctorate in naturopathic medicine is
from the National College of Naturopathic Medicine, a four-year graduate school
specializing in alternative medicine. She is licensed as a primary care
physician in the state of Washington and as an Advanced Practitioner of
Homeopathy in the state of Nevada. Dr. Even is a member of the Homeopathic
Pharmacopoeia Convention of the United States (HPCUS), the American Association
of Homeopathic Pharmacists (AAHP), and the Nevada Homeopathic and Integrative
Medical Association (NHIMA).

DR. MARCUS LAUX, ND will serve as a Medical Research Advisor in the areas of
Nutritional Science. He will also serve as Senior Associate Medical Research
spokesman for the NICOwater product line. He is a leading authority on
science-based natural medicines. Dr. Laux is a licensed naturopathic physician
with over a decade of private family practice. He received his doctorate from
National College of Naturopathic Medicine, Ptd, OR, where he serves as a
clinical professor. Dr. Laux is a leading authority on science-based natural
medicines, teaching continuing education seminars internationally for medical
doctors and pharmacists. He is former Chief Science Officer for Nutrition for
Life, Inc., and currently serves on several scientific Advisory Boards including
Phytopharmic Enzymatic Therapy, and Unigen Pharmacia.

DAVID L. ROSEN R.PH. J.D. has been retained as Medical Device and Product
Compliance Review Counsel. He is a partner in the Health Law Department in
McDermott, Will & Emery's Washington, D.C. office practicing primarily in the
areas of health law and food and drug regulation. Prior to entering private
practice, Mr. Rosen was employed at the F.D.A. for 14 years. While at the
F.D.A., Mr. Rosen, who has a pharmacy degree, worked as a consumer safety
officer with direct responsibility for evaluation and review of INDs, NDAs and
ANDAs. Mr. Rosen earned a bachelor's degree from the School of Pharmacy of the
University of Connecticut in 1978. He received his law degree from the Columbus
School of Law of Catholic University of America in 1991. He is admitted to
practice in Maryland and the District of Columbia.

WILLIAM OWEN will serve as QT 5's Government Contracts Consultant and Lobbyist.
Mr. Owen first became involved in Washington lobbying for A&E in 1993 working
with a national healthcare physicians' association to amend the Health Care
Reform Bill of 1994. Mr. Owen, a former Tennessee State Senator, served a total
of 12 years in the Tennessee General Assembly. During these years of public
service, he was secretary of the Senate's Transportation Committee, vice
chairman of the Education Committee, and vice chairman of the Majority Caucus.
He was also an active member of the Southern Legislative Conference's
Transportation Committee and the National Conference of State Legislature's
Communications and Transportation Committee. Mr. Owen currently serves on the
Democratic National Committee and the Tennessee State Democratic Executive
Committee. He is vice chairman of the Finance Committee. For the past six years
he has co-hosted and produced Democratic TeleVision, a monthly CATV program.

ABOUT QT 5, INC.
QT 5, Inc. (OTCBB:QTFV - News) was formed to be a developer, distributor, and
marketer of Bio-Med testing and Nutraceutical Beverage products. QT 5, Inc. is
continuing its clinical research and development of future products for
lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village,
California. For more information please visit: www.qt-5.com.

ABOUT NICOWATER
NICOWater(TM) is a water based nicotine product to provide "Adult Smokers an
Alternative to Smoking." This product is covered under a U.S. Patent.
NICOWater(TM) is not intended for use as a smoking cessation product. The
company believes that current labeling and materials are in full compliance with
the marketing standards in which it intends to sell.

FORWARD-LOOKING STATEMENTS
Forward-looking statements in this press release are made pursuant to the safe
harbor provisions of Section 21E of the Securities Exchange Act of 1934.
Investors are cautioned that statements in this press release that are not
strictly historical statements, including, without limitation, management's
plans and objectives for future operations, and management's assessment of
market factors, constitute forward-looking statements which involve risks and
uncertainties. These risks and uncertainties include, without limitation,
regulatory risks, the lack of acceptance of the Company's products by its
customers and prospects, the inability to secure the necessary product sales and
the inability to obtain necessary substantial additional capital to manufacture
and market its product and otherwise implement its business plan and other risks
detailed in QT 5's filings with the Securities and Exchange Commission, copies
of which may be accessed through the SEC's Web site at www.sec.gov. In each
case, actual results may differ materially from such forward-looking statements.
QT 5 does not undertake to publicly update or revise its forward-looking
statements, even if experience or future changes make it clear that any
projected results (expressed or modified) will not be realized.

[GRAPHIC OMITTED]
Contact:
     QT 5, Inc.
     Steve Reder, 818/338-1517
     or
     Capital Market Relations
     Chris Rosgen, 949/481-9739